Pre-earnings brief
Reports
Mon, Nov 2, 2026
Est. EPS
$0.12
Est. revenue
$166M
Implied move
±13.0%
EPS beat rate
63%
BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing innovative treatments for rare diseases. With a market cap of $2 billion, it operates in the health care sector, which is increasingly important as the demand for specialized medical solutions grows.
Last quarter
In Q2 2026, BioCryst reported an EPS of $0.30, significantly exceeding the expected $0.14, marking a strong performance. However, revenue details were not disclosed, leaving some uncertainty.
EPS beat streak
1Q
EPS beat rate
63%
Avg EPS surprise
-340.96%
Avg 1-day reaction
+0.90%
Analysts are cautiously optimistic about BioCryst's upcoming earnings, expecting a modest EPS of $0.12 and revenue of $166 million. The company has shown volatility in past earnings, leading to mixed investor sentiment.
Bull case
If BioCryst beats expectations again, it could signal strong demand for its products and boost investor confidence, potentially leading to a significant stock price increase.
Bear case
Conversely, if the company fails to meet expectations, it could reinforce concerns about its growth prospects and lead to a sharp decline in stock price.
Key metrics to watch
Earnings Per Share (EPS)
$0.12EPS is a key indicator of the company's profitability and financial health, showing how much profit is attributed to each share.
Revenue
$166MRevenue reflects the total income generated from the company's operations, which is crucial for assessing growth and market demand.
The print will turn on these.
Q1
Will BioCryst achieve at least $166 million in revenue this quarter?
This figure is crucial as it reflects the company's ability to generate income and meet market expectations.
Q2
Can BioCryst maintain or improve its EPS from last quarter's $0.30?
A strong EPS performance could indicate ongoing operational efficiency and product demand, which is vital for investor confidence.
—
Est. EPS
$-0.50
Est. Rev
$257M
Impl. Move
±7.5%
Why consensus could be wrong
The Street may be underestimating BioCryst's ability to sustain strong EPS growth given its recent performance and product pipeline.
Supporting evidence
The company has a history of surprising analysts with better-than-expected EPS.
Options pricing suggests traders anticipate significant movement, indicating potential for a positive surprise.
Key risk
If revenue comes in significantly below $166 million, it could undermine confidence in the company's growth trajectory.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will either reinforce the positive momentum from last quarter or highlight ongoing challenges.
Bull confirmed if
An EPS of $0.15 or higher would confirm the bull case and suggest strong underlying business performance.
Bear confirmed if
An EPS below $0.10 would confirm the bear case, indicating potential issues with revenue generation or cost management.
What the market is pricing for the move.
Implied Move
±22.05%
Historical Avg
±8.7%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±13.0% while BCRX has averaged ±8.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
44.3%
Smart-money positioning from the most recent 13F filings.
Institutional
105.31%
of float
Insider
1.28%
of float
Holders
418
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
23,893,036 sh · $200.7M
9.35%
5.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If BioCryst beats expectations, history suggests a potential stock increase of about 6.45%, confirming strong demand and operational success.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.
Miss
A miss could lead to a decline of around 8.34%, as investors reassess the company's growth prospects.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
RA Capital Management, L.P.
15,827,186 sh · $132.9M
6.19%
Flat
State Street Corporation
15,191,098 sh · $127.6M
5.94%
24.4%
Deerfield Management Company, L.P
15,096,403 sh · $126.8M
5.91%
0.4%
Vanguard Capital Management LLC
11,364,236 sh · $95.5M
4.45%
2.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded Jul 10, 2026 · disclosed Sep 4, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.